These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 19010156

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
    Wei-lin W, Jing J, Shu-sen Z, Li-hua W, Ting-bo L, Song-feng Y, Sheng Y.
    Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
    [Abstract] [Full Text] [Related]

  • 5. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A.
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
    Mendes J, Martinho A, Simoes O, Mota A, Breitenfeld L, Pais L.
    Transplant Proc; 2009 Apr; 41(3):840-2. PubMed ID: 19376366
    [Abstract] [Full Text] [Related]

  • 11. Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.
    Buendía JA, Otamendi E, Kravetz MC, Cairo F, Ruf A, de Davila M, Powazniak Y, Nafissi J, Lazarowski A, Bramuglia G, Villamil F.
    Exp Clin Transplant; 2015 Oct; 13(5):441-8. PubMed ID: 26450467
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
    Tirelli S, Ferraresso M, Ghio L, Meregalli E, Martina V, Belingheri M, Mattiello C, Torresani E, Edefonti A.
    Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients.
    Min SI, Kim SY, Ahn SH, Min SK, Kim SH, Kim YS, Moon KC, Oh JM, Kim SJ, Ha J.
    Transplantation; 2010 Dec 27; 90(12):1394-400. PubMed ID: 21076384
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Association of CYP3A5 and MDR1 genetic polymorphisms with the blood concentration of tacrolimus in Chinese liver and renal transplant recipients].
    Sun JY, Wang XG, Zou YG, Wang YP, Liang DR, Liang MZ, Miao J.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Jul 27; 44(4):573-7. PubMed ID: 24059111
    [Abstract] [Full Text] [Related]

  • 18. The impact of CYP3A5 and MDR1 polymorphisms on tacrolimus dosage requirements and trough concentrations in pediatric renal transplant recipients.
    Shilbayeh S, Zmeili R, Almardini RI.
    Saudi J Kidney Dis Transpl; 2013 Nov 27; 24(6):1125-36. PubMed ID: 24231473
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
    Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, de Fijter JW, Guchelaar HJ.
    Ther Drug Monit; 2009 Apr 27; 31(2):187-97. PubMed ID: 19258929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.